Literature DB >> 15071611

Factors affecting pharmacokinetics of monoclonal antibodies: A review article.

N Iznaga-Escobar1, A K Mishra, R Perez-Rodriguez.   

Abstract

Factors affecting the successful therapy of malignant diseases include the antibody dose used and the schedule of administration, the half-life and fast blood clearance of the antibodies, the presence of circulating antigen, poor tumor penetration of the high/molecular-weight monoclonal antibody (mAb) and the way in which these molecules are catabolized. To circumvent these limitations and achieve higher uptake, increased tumor penetration, faster blood clearance and longer retention in the tumors, there is a need to generate mAbs suitable for diagnosis as well as therapy and to develop novel strategies to increase the efficacy of immunotherapeutic treatments. There is a lack of knowledge about many aspects of the physiological function and metabolism of antibodies. This paper is intended to discuss factors that affect the pharmacokinetics of mAbs in human subjects with the purpose of forming possible strategies to optimize this approach for tumor diagnosis and therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15071611     DOI: 10.1358/mf.2004.26.2.800065

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  5 in total

1.  Weak interactions govern the viscosity of concentrated antibody solutions: high-throughput analysis using the diffusion interaction parameter.

Authors:  Brian D Connolly; Chris Petry; Sandeep Yadav; Barthélemy Demeule; Natalie Ciaccio; Jamie M R Moore; Steven J Shire; Yatin R Gokarn
Journal:  Biophys J       Date:  2012-07-03       Impact factor: 4.033

2.  Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats.

Authors:  Leslie A Khawli; Sirj Goswami; Ryan Hutchinson; Zephania W Kwong; Jihong Yang; Xiangdan Wang; Zhenling Yao; Alavattam Sreedhara; Tony Cano; Devin Tesar; Ihsan Nijem; David E Allison; Pin Yee Wong; Yung-Hsiang Kao; Cynthia Quan; Amita Joshi; Reed J Harris; Paul Motchnik
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

3.  A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

Authors:  Seunguk Oh; Deborah A Todhunter; Angela Panoskaltsis-Mortari; Donald J Buchsbaum; Shoko Toma; Daniel A Vallera
Journal:  Pancreas       Date:  2012-07       Impact factor: 3.327

Review 4.  Review: update on selection of optimal radiopharmaceuticals for clinical trials.

Authors:  Lawrence E Williams; George Lopatin; Daniel D Kaplan; An Liu; Jeffrey Y C Wong
Journal:  Cancer Biother Radiopharm       Date:  2008-12       Impact factor: 3.099

5.  Pharmacokinetic comparison of a diverse panel of non-targeting human antibodies as matched IgG1 and IgG2 isotypes in rodents and non-human primates.

Authors:  Kenneth W Walker; Hossein Salimi-Moosavi; Gregory E Arnold; Qing Chen; Marcus Soto; Frederick W Jacobsen; John Hui
Journal:  PLoS One       Date:  2019-05-23       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.